Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
1vx1qYMwDC62hmMJ
